Posted by Michael Wonder on 01 Mar 2021
Vetex Medical receives FDA clearance for Revene thrombectomy catheter
1 March 2021 - Patented dynamic cage technology designed to predictably remove wall-adherent clot in peripheral veins, such as deep vein thrombosis, in single session without thrombolytics.
Vetex Medical today announced U.S. FDA 510(k) clearance for the ReVene Thrombectomy Catheter. ReVene uses dual-action technology designed to de-clot peripheral vessels, such as in deep vein thrombosis, through wall-to-wall contact in a single session without the use of thrombolytics.
The device is expected to be commercially available in the U.S. later in the year.
